Accolade, Inc. (NASDAQ:ACCD) EVP Richard Eskew Sells 3,581 Shares

Accolade, Inc. (NASDAQ:ACCD) EVP Richard Eskew sold 3,581 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $3.60, for a total value of $12,891.60. Following the completion of the transaction, the executive vice president now directly owns 62,507 shares in the company, valued at approximately $225,025.20. This represents a 5.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Richard Eskew also recently made the following trade(s):

• On Monday, November 4th, Richard Eskew sold 336 shares of Accolade stock. The stock was sold at an average price of $3.15, for a total value of $1,058.40.
• On Wednesday, October 2nd, Richard Eskew sold 334 shares of Accolade stock. The stock was sold at an average price of $3.70, for a total value of $1,235.80.

Accolade Stock Down 0.8 %

Shares of ACCD traded down $0.03 during midday trading on Wednesday, reaching $3.54. 687,313 shares of the stock were exchanged, compared to its average volume of 1,094,706. Accolade, Inc. has a 52 week low of $3.08 and a 52 week high of $15.36. The company has a current ratio of 2.72, a quick ratio of 2.72 and a debt-to-equity ratio of 0.49. The company’s 50 day moving average is $3.60 and its two-hundred day moving average is $4.38. The company has a market capitalization of $285.11 million, a P/E ratio of -3.44 and a beta of 2.07.

Accolade (NASDAQ:ACCD) last issued its quarterly earnings data on Tuesday, October 8th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.14. The firm had revenue of $106.40 million during the quarter, compared to analysts’ expectations of $104.87 million. Accolade had a negative return on equity of 18.43% and a negative net margin of 18.16%. The firm’s quarterly revenue was up 9.8% on a year-over-year basis. During the same period in the prior year, the business posted ($0.43) EPS. On average, sell-side analysts anticipate that Accolade, Inc. will post -0.92 earnings per share for the current year.

Institutional Investors Weigh In On Accolade

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mission Creek Capital Partners Inc. purchased a new stake in Accolade in the third quarter valued at about $38,000. IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in Accolade in the third quarter valued at about $46,000. SG Americas Securities LLC purchased a new stake in Accolade in the second quarter valued at about $43,000. Wolverine Trading LLC purchased a new stake in Accolade in the third quarter valued at about $51,000. Finally, Price T Rowe Associates Inc. MD raised its stake in Accolade by 15.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,540 shares of the company’s stock valued at $205,000 after buying an additional 2,586 shares during the last quarter. 84.99% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Wells Fargo & Company lowered their price target on Accolade from $7.00 to $6.00 and set an “equal weight” rating on the stock in a report on Friday, October 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Accolade in a report on Monday, October 7th. Stephens decreased their price objective on Accolade from $10.00 to $8.00 and set an “overweight” rating on the stock in a report on Wednesday, October 9th. Canaccord Genuity Group decreased their price objective on Accolade from $13.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. Finally, Truist Financial decreased their price objective on Accolade from $9.00 to $7.50 and set a “buy” rating on the stock in a report on Wednesday, October 9th. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, Accolade currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.04.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.